WST
WEST PHARMACEUTICAL SERVICES, INC.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q4 2020 | 23Q | $287 | $304 | +6% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $291 | $304 | +5% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $291 | $304 | +5% |
| D.E. Shaw re-entered | Q3 2024(8Q snapshot) | 7Q | $291 | $304 | +5% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $291 | $304 | +5% |
| Millennium Management re-entered | Q3 2024(8Q snapshot) | 7Q | $291 | $304 | +5% |
| Point72 Asset Management | Q1 2025(8Q snapshot) | 5Q | $214 | $304 | +42% |
| Renaissance Technologies re-entered | Q3 2025(8Q snapshot) | 3Q | $246 | $304 | +24% |
| Viking Global Investors | Q1 2026 | 1Q | $243 | $304 | +25% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Maverick Capital 3× in & out | Q2 2024 | Q3 2024 | → $291 | -17% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at WEST PHARMACEUTICAL SERVICES INC. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from May 14, 2026 — the most recent Form 4 on file — not from today.
- Form 40000105770-26-000075May 14, 2026
- Form 40000105770-26-000066May 6, 2026
- Form 40000105770-26-000065May 6, 2026
- Form 40000105770-26-000064May 6, 2026
- Form 40000105770-26-000063May 6, 2026
- Form 40000105770-26-000062May 6, 2026
- Form 40000105770-26-000061May 6, 2026
- Form 40000105770-26-000060May 6, 2026
- Form 40000105770-26-000059May 6, 2026
- Form 40000105770-26-000058May 6, 2026
- Form 40000105770-26-000057May 6, 2026
- Form 40000105770-26-000054Apr 29, 2026
- Form 40000105770-26-000053Apr 29, 2026
- Form 40000105770-26-000043Apr 1, 2026
- Form 40000105770-26-000039Mar 3, 2026
Fundamentals
XBRL · WEST PHARMACEUTICAL SERVICES, INC.Annual figures sourced directly from WEST PHARMACEUTICAL SERVICES, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for WEST PHARMACEUTICAL SERVICES INC — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 1, 2026
- 8-K/AMaterial event (amended)May 20, 2026
- 8-KMaterial eventMay 11, 2026
- 8-KMaterial eventMay 5, 2026
- 10-QQuarterly reportApr 23, 2026
- 8-KMaterial eventApr 23, 2026
- DEF 14AProxy statementMar 12, 2026
- 8-KMaterial eventMar 9, 2026
- 10-KAnnual reportFeb 17, 2026
- 8-KMaterial eventFeb 12, 2026
- 10-QQuarterly reportOct 23, 2025
- 8-KMaterial eventOct 23, 2025
- 8-KMaterial eventSep 11, 2025
- 10-QQuarterly reportJul 24, 2025
- 8-KMaterial eventJul 24, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| D.E. Shaw | Q2 2026 | open | $303 | $304 | +1% |
| Viking Global Investors | Q1 2026 | open | $243 | $314 | +29% |
| Bridgewater Associates | Q1 2026 | open | $250 | $314 | +26% |
| Renaissance Technologies | Q1 2026 | open | $243 | $304 | +25% |
| Renaissance Technologies | Q3 2025 | Q4 2025 | $246 | $266 | +8% |
| Millennium Management | Q1 2025 | open | $214 | $304 | +42% |
| Point72 Asset Management | Q1 2025 | open | $214 | $304 | +42% |
| Citadel Advisors | Q3 2024 | open | $291 | $304 | +5% |
| Two Sigma Investments | Q3 2024 | open | $291 | $304 | +5% |
| D.E. Shaw | Q3 2024 | Q1 2026 | $291 | $243 | -16% |
| AQR Capital Management | Q3 2024 | open | $291 | $304 | +5% |
| Millennium Management | Q3 2024 | Q4 2024 | $291 | $336 | +16% |
| Maverick Capital | Q2 2024 | Q3 2024 | $349 | $291 | -17% |
| Maverick Capital | Q3 2021 | Q1 2022 | $436 | $379 | -13% |
| Bridgewater Associates | Q4 2020 | Q3 2024 | $287 | $291 | +1% |
| Maverick Capital | Q4 2018 | Q3 2019 | $104 | $140 | +34% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.